Production and in vitro characterization of lisinopril-loaded nanoparticles for the treatment of restenosis in stented coronary arteries

References

• Baker RW, Lonsdale HK. Controlled release: Mechanisms and rates. Controlled release of biologically active agents, AC Tanquary, RF Lacey. Plenum Press, New York 1974; 15–71
   Google Scholar
• Banai S, Chorny M, Gertz SD, Fishbein I, Gao J, Perez L, Lazarovichi G, Gazit A, Levitzki A, Golomb G. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials 2005; 26: 451–461
   PubMed Web of Science ®Google Scholar
• Binks BP, Lumsdon SO. Influence of particle wettability on the type and stability of surfactant-free emulsions. Langmuir 2000; 16: 8622–8631
   Web of Science ®Google Scholar
• Budhian A, Siegel SJ, Winey KI. Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int J Pharm 2008; 346: 151–159
   PubMed Web of Science ®Google Scholar
• Chorny M, Fishbein I, Golomb G. Drug delivery systems for the treatment of restenosis. Crit Rev Ther Drug Carrier Syst 2000; 17: 49–284
   Web of Science ®Google Scholar
• Eccleston DS, Lincoff AM. Catheter-based drug delivery for restenosis. Adv Drug Deliv Rev 1997; 24: 31–43
   Web of Science ®Google Scholar
• El-Gindy A, Ashour A, Abdel-Fattah L, Shabana MM. Spectrophotometric, septrofluorimetric and LC determination of lisinopril. J Pharm Biomed Anal 2001; 25: 913–922
   PubMed Web of Science ®Google Scholar
• Ettenson DS, Edelman ER. Local drud delivery: An emerging approach in the treatment of restenosis. Vasc Med 2000; 5: 97–102
   PubMed Web of Science ®Google Scholar
• Fishbein I, Chorny M, Banai S, Levitzki A, Danenberg HD, Gao J, Chen X, Moerman E, Gati I, Goldwasser V, et al. Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler Thromb Vasc Biol 2001; 21: 1434–1439
   PubMed Web of Science ®Google Scholar
• Gershlick AH. Treating atherosclerosis: Local drug delivery from laboratory studies to clinical trials. Atherosclerosis 2002; 160: 259–271
   PubMed Web of Science ®Google Scholar
• Gohel MC, Panchal MK. Novel use of similarity factors f2 and Sd for development of diltiazem HCl modified-Release tablets using a 32 factorial design. Drug Dev Ind Pharm 2002; 28: 77–87
   PubMed Web of Science ®Google Scholar
• Gupta KC, Jabrail FH. Glutaraldehyde and glyoxal cross-linked chitosan microspheres for controlled delivery of centchroman. Carbohyd Res 2006; 341: 744–756
   PubMed Web of Science ®Google Scholar
• Guzman LA, Labhasetwar V, Song C, Jang Y, Lincoff AM, Levy R, Topol EJ. Local intraluminal infusion of biodegradable polymeric nanoparticles—a novel approach for prolonged drug delivery after balloon angioplasty. Circulation 1996; 94: 1441–1448
   PubMed Web of Science ®Google Scholar
• Haskell RJ. Physical characterization of nanoparticles. Nanoparticle technology for drug delivery, RB Gupta, UB Kompella. Taylor & Francis Group, New York 2006; 119–120
   Google Scholar
• Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963; 52: 1145–1149
   PubMed Web of Science ®Google Scholar
• Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. I. Theoretical consideration. Ind Eng Chem 1931; 23: 923–931
   Google Scholar
• Itoh T, Nonogi H, Miyazaki S, Itoh A, Daikoku S, Morii I, Goto Y. Local delivery of argatroban for the prevention of restenosis after coronary balloon angioplasty: A propective randomized pilot study. Circulat J 2004; 68: 615–622
   PubMed Web of Science ®Google Scholar
• Kavanagh CA, Rochev YA, Gallagher WM, Dawson KA, Keenan AK. Local drug delivery in restenosis injury: Thermoresponsive co-polymers as potential drug delivery systems. Pharmacol Ther 2004; 102: 1–15
   PubMed Web of Science ®Google Scholar
• Kawaguchi H. Functional polymer microspheres. Prog Polym Sci 2000; 25: 1171–1210
   Web of Science ®Google Scholar
• Kronberg B, Kall L, Stenius P. Adsorption of nonionic surfactants on latexes. J Dispersion Sci Tech 1981; 2: 215–232
   Web of Science ®Google Scholar
• Labhasetwar V, Levy RJ. Implants for site-specific drug delivery. J App Biomat 1991; 2: 211–212
   PubMedGoogle Scholar
• Labhasetwar V, Song C, Humphrey W, Shebuski R, Levy RJ. Arterial uptake of biodegradable nanoparticles: Effect of surface modifications. J Pharm Sci 1998; 87: 1229–1234
   PubMed Web of Science ®Google Scholar
• Labhasetwar V, Song CX, Levy RJ. Nanoparticle drug delivery systems for restenosis. Adv Drug Del Rev 1997; 24: 63–85
   Web of Science ®Google Scholar
• Leroux JC, Allémann E, Gurny R, Doelker E. New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur J Pharm Biopharm 1995; 41: 14–18
   Web of Science ®Google Scholar
• Li Wan Po A, Wong LP, Gilligan CA. Characterisation of commercially available theophylline sustained- or controlled-release systems: In vitro drug release profiles. Int J Pharm 1990; 66: 111–130
   Google Scholar
• Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis: Fact, fancy, and future. Circulation 1994; 90: 2070–2084
   PubMed Web of Science ®Google Scholar
• Ren S, Park MJ, Sah H, Lee BJ. Effect of pharmaceutical excipients on aqueous stability of rabeprazole sodium. 2008, 197–204 In J Pharm. 350(1–2)
   Google Scholar
• Rensing BJ, Vos J, Smits PC, Foley DP, Van den Brand MJ, Van der Giessen WJ, de Feijter PJ, Serrys PW. Coronary restenosis elimination with a sirolimos elutingstent–First European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J, 22: 2125–2130
   PubMed Web of Science ®Google Scholar
• Sagirli O, Ersoy L. An HPLC method for the determination of lisinopril in human plasma and urine with fluorescence detection. J Chromatog B 2004; 809: 159–165
   PubMed Web of Science ®Google Scholar
• Song CX, Labhasetwar V, Murphy H, Qu X, Humphrey WR, Shebuski RJ, Levy RJ. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Contr Rel 1997; 43: 197–212
   Web of Science ®Google Scholar
• Sturek M, Reddy HK. New tools for prevention of restenosis could decrease the ‘oculo-stento’ reflex. Cardiovasc Res 2002; 53: 292–293
   PubMed Web of Science ®Google Scholar
• Tambe DE, Sharma MM. The effect of colloidal particles on fluid–fluid interfacial properties and emulsion stability. J Colloid Interface Sci 1994; 52: 1–63
   Web of Science ®Google Scholar
• Tep G, Duda SH, Kalinowski M, Kamenz J, Brehme U, Hanke H, Claussen CD, Bares R, Baumbach A, Dinkelborg LM. Local intra-arterial drug delivery for prevention of restenosis: Comparison of the efficiency of delivery of different radiopharmaceuticals through a porous catheter. Invest Radiol 2001; 36: 245–249
   PubMed Web of Science ®Google Scholar
• Vijayaraghavan K, Deedwania PC. The rennin angiotensin system as a therapeutic target to prevent diabetes and its complications. Cardiol Clin 2005; 23: 165–183
   PubMed Web of Science ®Google Scholar
• Zweers MLT, Engbers GHM, Grijpma DW, Feijen J. Release of anti-restenosis drugs from poly(ethylene oxide)-poly(dl-lactic-co-glycolic acid) nanoparticles. J Contr Rel 2006; 114: 317–324
   PubMed Web of Science ®Google Scholar